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Abstract 
Background: The ARTemis trial previously reported that addition of neoadjuvant 
bevacizumab (Bev) to docetaxel followed by fluorouracil, epirubicin and 
cyclophosphamide (D-FEC) in HER2 negative breast cancer improved the 
pathological complete response (pCR) rate. We present disease-free (DFS) and 
overall survival (OS) with central pathology review. 
 
Patients and Methods: Patients were randomised to 3 cycles of D followed by 3 
cycles of FEC (D-FEC), ± 4 cycles of Bev (Bev+D-FEC). DFS and OS were analysed 
by treatment and by central pathology reviewed pCR and Residual Cancer Burden 
(RCB) categories. 
 
Results: 800 patients were randomised (median follow-up 35 yrs (IQR 32–44)). 
DFS and OS were similar across treatment arms (DFS: hazard ratio (HR)=118 
(95%CI 089-157), P=025. OS: HR=126 (95%CI 090-176), P=019). Both local 
pathology report review and central histopathology review confirmed a significant 
improvement in DFS and OS for patients who achieved a pCR (DFS HR=038 
(95%CI 023-063), P<0001: OS HR=043 (95%CI 024-075), P=0003). However, 
significant heterogeneity was observed (P=002); larger improvements in DFS were 
obtained with a pCR achieved with D-FEC than a pCR achieved with Bev+D-FEC. 
As RCB category increased, significantly worse DFS and OS was observed (P for 
trend <00001), which effect was most marked in the ER negative group. 
 
Conclusions: The addition of short course neoadjuvant Bev to standard 
chemotherapy did not demonstrate a DFS or OS benefit. Achieving a pCR with D-
FEC is associated with improved DFS and OS but not when pCR is achieved with 
Bev+D-FEC. At the present time therefore, Bev is not recommended in early breast 
cancer (ClinicalTrials.gov number NCT01093235). 
 
ClinicalTrials.gov (NCT 01093235). 
 
Key Words: ARTemis, breast cancer, bevacizumab, neoadjuvant chemotherapy. 
 
Key Message 
The ARTemis trial was a neoadjuvant study of standard chemotherapy (D-FEC) +/- 
short course bevacizumab (Bev). The addition of Bev improved pathological 
response (pCR) rates. However disease-free and overall survival was not improved 
and patients on the Bev arm who achieved a pCR did not seem to have the same 
survival benefit from achieving a pCR as did patients receiving standard 
chemotherapy. 
 
  
INTRODUCTION 
The ARTemis trial was designed to test the hypothesis that adding bevacizumab 
(Bev) [1, 2], to standard neo-adjuvant chemotherapy would improve pathological 
complete response rates (pCR), and longer-term outcomes for HER2 negative early 
breast cancer. Assessed by a two-reader blinded review of local pathology reports, 
the addition of four cycles of Bev to D-FEC was found to improve pCR rates (22% for 
Bev+D-FEC patients,17% for D-FEC patients, adjusted P=003) [3]. Other 
neoadjuvant trials (GeparQuinto [4], CALGB 40603 [5] and NSABP-B40 study [6]), 
also showed an improvement in pCR rates with the addition of Bev to neoadjuvant 
chemotherapy. However adjuvant Bev in the BEATRICE study in TNBC patients [7] 
and in the ECOG 5103 study [8], showed no improvement in invasive disease-free 
(IDFS) or overall survival (OS). Both of these adjuvant trials used a year of Bev in 
the experimental arm, as did the NSABP-B40. In contrast shorter courses of Bev, 
were used in the other trials: 4 cycles at 15mg/kg every 3 weeks (q3w) in ARTemis; 
8 cycles at 15mg/kg q3w in GeparQuinto; and 9 cycles at 10mg/kg q2w in CALGB 
40603. 
 
A central pathological review of diagnostic and surgical excision histopathology 
slides was undertaken (manuscript submitted Nov 2016) which included Residual 
Cancer Burden (RCB) categories [9]. Using these analyses, we present here the 
secondary endpoints of DFS and OS for the ARTemis trial to assess whether the 
increase in pCR rate results in improved longer-term outcomes. 
 
METHODS 
ARTemis is an investigator designed and led, open label randomised, phase III trial 
approved by the South-East England Multi-Centre Research Ethics Committee and 
the Research and Development departments at all participating centres. It was 
granted a Clinical Trials Authorisation (CTA) from the Medicines and Healthcare 
products Regulatory Agency (MHRA) on Feb 25, 2009. Trial co-ordination was 
supported by a Cancer Research UK project grant (CRUK/08/037). An unrestricted 
educational grant and free Bev was provided by Roche and an unrestricted 
educational grant by Sanofi. 
 
STUDY DESIGN 
Full details of the design, sample size, eligibility, stratification and treatments have 
been described elsewhere [3]. Eligibility included women with a histological 
diagnosis of non-metastatic HER2 negative invasive breast cancer, and a 
radiological tumour size of >20 mm with or without axillary involvement. All patients 
provided written informed consent and could commence chemotherapy within one 
week of randomisation. Patients with inflammatory cancer, T4 tumours with direct 
extension to the chest wall or skin, and ipsilateral supraclavicular lymph node 
involvement were eligible with any size of primary tumour. The two randomised 
treatments were: three cycles of docetaxel (100 mg/m2 once every 21 days) followed 
by three cycles of fluorouracil, epirubicin, and cyclophosphamide (500:100:500 
mg/m2) once every 21 days (D-FEC), with or without four cycles of bevacizumab (15 
mg/kg) (Bev+D-FEC) commencing with the first cycle of Docetaxel. 
 
PATIENTS 
Patients were randomly assigned (1:1) by telephone to the Warwick Clinical Trials 
Unit. Using a central computerised minimisation procedure, stratification was by age 
(≤50: >50), ER status (strongly positive (Allred 6-8): weakly positive (Allred 3-5): 
negative (Allred ≤ 2)), total tumour size (≤5cm: >5cm), clinical involvement of axillary 
lymph nodes (yes: no) and disease type (inflammatory and/or locally advanced: 
neither). 
 
CENTRAL PATHOLOGY SPECIMEN REVIEW 
Two breast pathologists on the trial management group reviewed, blind to local 
pathology reports and patient outcomes, all collected histopathology slides for 
response (pCR and RCB) [9]  
 
STATISTICAL ANALYSIS 
OS was calculated from date of randomisation to date of death from any cause, or 
date of censoring if alive. DFS was calculated from date of randomisation to date of 
first relapse (loco-regional or distant, not including DCIS); to date of death in women 
dying without invasive relapse; or to date of censoring in women alive and disease-
free. Survival curves were constructed using Kaplan–Meier methodology and 
assessed using log-rank tests. Cox-proportional hazards modelling was used to 
investigate treatment effects, whilst adjusting for stratification variables. Hazard 
ratios of treatment effects on the risk of relapse and death for each of the stratified 
subgroups were displayed on HR plots [10]. To assess the association between 
response to neo-adjuvant treatment and DFS and OS, a landmark analysis was 
undertaken recalculating times from date of surgery. Pathological response rates 
were assessed across randomised treatment arms using chi-squared tests, with 
continuity correction where appropriate, and logistic regression to adjust for 
stratification factors. 
 
We report the protocol-stated pre-planned interim analysis of DFS and OS with at 
least 120 events (median follow-up 3 years). All analyses were undertaken by 
Warwick Clinical Trials Unit with SAS statistical software (version 93). Protocol 
violators were analysed within their randomised groups on an intention-to-treat basis. 
All reported p-values are two-sided. ARTemis is registered with EudraCT (2008-
002322-11), ISRCTN (68502941), and ClinicalTrials.gov (NCT01093235). 
 
  
RESULTS 
PATIENT CHARACTERISTICS 
800 patients were randomised into ARTemis between May 2009 and January 2013; 
399 to Bev+D-FEC, 401 to D-FEC (Figure 1, Table 1). Patient characteristics were 
balanced across randomised treatment arms [3]. The distribution of important 
prognostic factors in the subgroups with available central pathology review was 
similar to the full trial (Table 1). 
 
CENTRAL PATHOLOGY REVIEW AND pCR RATES 
The original analysis of the primary endpoint of pCR on the 781 patients who had 
surgery within the trial used a 2-reader independent review of local pathology reports 
(Figure 1). This allowed detection of absolute differences between treatment arms in 
the pCR rates >10% at the 5% (2-sided) level of significance (85% power). 
Histopathology slide retrieval was successful in obtaining a full slide set in 681/781 
pts (87%). This ensured that the central pathological review allowed detection of the 
same 10% differences (power reduced to 80%). Patients with positive pre-treatment 
sentinel lymph node biopsy (SLNB) were excluded from RCB assessment, as per 
the guidelines [9] leaving 587/681 patients (86%) with calculated RCB (Figure 1). 
 
In the original publication, based on the 2-reader report review, pCR was reported for 
153/781 pts (20%) [3]. For patients who had central pathological review (n=681), 
pCR was reported in 130/681 pts (19%), with a higher pCR rate for Bev+D-FEC pts 
(77/344 [22%] versus 53/337 [16%] for D-FEC patients; adjusted P=003, Table 2). 
Amongst the 587 patients with assessable RCB, treatment with bevacizumab 
resulted in a shift towards better (lower) RCB categories (adjusted P for trend=0004; 
Table 2). 
 
DISEASE-FREE AND OVERALL SURVIVAL 
At the data lock (14th April 2016), 136/800 (17%) patients had died (Figure 1). The 
median follow-up for alive pts was 35 years, with 82% of alive pts having >3 years 
follow-up. The main cause of death was breast cancer (98% [133/136] of patients 
who died). 72 patients have a local relapse, and 151 patients a distant relapse, 
predominantly in the bone, liver and/or lung (81% of patients who have a distant 
relapse). 47 patients reported a local and distant relapse. There are 191 events in 
the DFS analysis (24%). 
 
There were no significant differences detected in DFS or OS between the two 
randomised treatment arms (DFS HR 118 [95%CI 089-157], P=025, Figure 2a; 
OS HR 126 [95%CI 090-176], P=019, Figure 2b). There was evidence 
of heterogeneity only in the treatment effect on DFS for patients with clinically 
negative nodes at diagnosis (heterogeneity P=002, not adjusted for multiple 
comparisons) (Figure S1a). Otherwise no heterogeneity was observed in the 
treatment effect on DFS and OS across all patient characteristics (Figure S1b). 
However, there appeared to be a slightly worse DFS and OS for ER strongly positive 
patients treated with Bev (Figure S2). 
 
DFS AND OS FROM SURGERY BY pCR 
The landmark analysis, investigating the effect of pathological response on DFS and 
OS, included 677/681 patients. 109/677 (16%) subsequently died, and 157/677 
(23%) subsequently had a DFS event. Analysis of DFS events in the pCR group 
(Table S1) demonstrated that, although more patients achieved a pCR in the Bev+D-
FEC arm (22% v 16% for D-FEC), 16/77 (16%) had a DFS event compared with only 
3/52 (6%) in the D-FEC arm. 
 
There was a significant improvement in both DFS and OS for patients obtaining pCR 
(DFS HR 038 (95%CI 023-063), P<0001, Figure S3a; OS HR 043 (95%CI 024-
075), P=0003, Figure S3d). However, there was significant heterogeneity in 
treatment effect on DFS between patients achieving pCR or not (P=002) and 
according to RCB categories (P=003) (Figure 3a). Importantly, patients achieving 
pCR in the Bev+D-FEC arm had a risk of a DFS event that was 299-fold higher 
(95%CI 120-745) than that for patients achieving pCR in the D-FEC arm (Figure 
3a). Similar findings, although non-significant, were seen for OS (P=019 for pCR 
and P=005 for RCB categories) (Figure 3b). DFS and OS curves plotted by 
treatment arm demonstrated this larger improvement in D-FEC patients (Figure S3c 
and S3f) (Figure S3b and S3e). As RCB category increased, significantly worse DFS 
and OS was observed (both P for trend <00001, Figure S4a and S4d) and, similar to 
pCR, with differing treatment effects across the categories (DFS heterogeneity 
P=003 Figure 3a, OS heterogeneity P=005 Figure 3b). An additional analysis of 
DFS and OS by RCB for ER groups is shown (Figure S5). 
 
DISCUSSION 
The ARTemis trial results reported here demonstrate no advantage for short course 
neo-adjuvant Bev in terms of DFS and OS at a median follow-up of 35 years and 
these results are similar to those of GeparQuinto [11] and CALGB-40603 [12]. It has 
been shown in most neoadjuvant breast cancer trials that longer term outcomes, 
analysed by treatment arm, fail to show a benefit even when there are significant 
improvements in pCR rates. It is now understood that this is due to a complexity of 
interacting factors [13-15], the most obvious of which is the smaller number of 
patients required in neoadjuvant trials. Only one neoadjuvant trial in HER2 positive 
breast cancer adding trastuzumab to standard chemotherapy showed improved long 
term outcomes by treatment arm [16]. 
 
Pooled analyses [17, 18] have shown that patients achieving pCR have significantly 
better DFS and OS, than other patients. However, ARTemis shows that gaining a 
pCR for patients with the addition of Bev, does not appear to have this benefit, and 
the outcomes for these patients are not significantly better than for those not 
achieving a pCR. This is clearly demonstrated both by the Kaplan-Meier DFS and 
OS curves by pCR and treatment arms (Figure S3), and in the forest plots (Figure 3). 
This result has led to our hypothesis [3] that although Bev improves pCR rates by its 
effect in the angiogenesis-dependent primary tumour, it has no effect on putative 
angiogenesis-independent micro-metastatic disease. This hypothesis would also 
explain the negative long-term results from GeparQuinto and CALGB-40603 [12, 13] 
and adjuvant BEATRICE and ECOG studies [7, 8]. Similar negative results have 
been found in adjuvant studies in colorectal cancer [19] and melanoma [20]. In 
contrast, in epithelial ovarian cancer (EOC) in the first line setting [21, 22] positive 
long-term results have been shown probably for two reasons; firstly the majority of 
patients had macroscopic residual disease post-surgery which is angiogenesis-
dependent; and secondly there may be an autocrine effect of VEGF directly on 
receptors on ovarian cancer cells [23]. 
 Intriguingly, the ARTemis data hint at the possibility that patients in the experimental 
arm do non-significantly but slightly worse than the standard arm (Fig S1). One 
explanation is the possible increased populations of classically chemo-resistant 
breast cancer stem cells in tumours due to the hypoxia generated by Bev [24]. In 
addition, there is possibly a group for whom Bev is having a detrimental effect. This 
has been reported in EOC where an ‘immunological signature’ with a better 
prognosis was associated with a negative interaction with Bev [25]. We plan 
translational research to discover whether there are similar molecular signatures in 
ARTemis. 
 
Our central pathology review and analysis of RCB categories has provided some 
interesting additional results. Bev shows a benefit in terms of the proportion of 
patients achieving pCR, but there is no improvement in survival for patients 
achieving a pCR. Central review confirms these findings from the two-reader report 
review [3]. 
 
In conclusion the ARTemis trial, shows that although the addition of Bev to taxane-
anthracycline-based chemotherapy increases pCR rates it does not provide a 
corresponding benefit in terms of DFS and OS. 
 
ACKNOWLEDGMENTS 
The trial was funded by Cancer Research UK (CRUK/08/037 for trial coordination), 
Roche (provision of free study drug bevacizumab and unrestricted educational grant 
for trial coordination), and Sanofi (unrestricted educational grant for trial 
coordination). We acknowledge the 116 investigators (in particular Dr Stephen 
Houston) and their teams from 66 participating UK centres who entered patients into 
the ARTemis trial. Our gratitude also goes to the 800 women who kindly participated 
in our study. We thank the data and safety monitoring committee members: I Craig 
Henderson (University of California, San Francisco, CA, USA), Luca Gianni 
(Ospedale San Raffaele, Milan, Italy), Mark F Brady (Gynecologic Oncology Group 
Statistical & Data Center, Roswell Park Cancer Institute, Buffalo, NY, USA), and 
Xavier Pivot (Centre Hospitalier Regional Universitaire et Institut Régional Fédératif 
de Cancérologie, Besançon, France). We thank the trials unit staff: phase 3 
coordination at Warwick Clinical Trials Unit, Coventry, UK; translational coordination 
at University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK and University 
of Edinburgh Department of Oncology (BioBank); and statistical analysis at Warwick 
Clinical Trials Unit, UK. 
 
FUNDING 
This work was supported by Cancer Research UK with a project grant number 
CRUK/08/037 (2009-18); Roche and Sanofi provided unrestricted educational grants 
to the ARTemis trial; and Roche provided free bevcizumab for use in the trial. 
 
DISCLOSURE 
HME received funding from Cancer Research UK for trial coordination, Roche for 
trial coordination and free bevacizumab, and Sanofi for trial coordination. RLH 
received funding through the University of Cambridge (as sponsors of the trial) from 
Cancer Research UK, Roche, and Sanofi, and disbursed the proportion due to NHS 
Lothian for work on the trial; and personal fees from Roche for attendance at 
advisory board and international meetings. LH, JAD, and CB received grants from 
Cancer Research UK and Cambridge University Hospitals NHS Foundation Trust. 
LG reports grant and non-financial support from Roche, and grants from Sanofi and 
Cancer Research UK. KM reports personal fees from Roche teaching evaluation, 
personal fees from Roche Advisory Board and Roche sponsored meeting and 
speaker fees, outside the submitted work. DR reports personal fees from Roche, 
outside the submitted work. CC reports grants from Genetech, AstraZeneca and 
Roche, outside the submitted work; and is a member of AstraZeneca's Scientific 
Advisory Board. JB reports consultancy and advisory roles from Insight Genetics, 
BioNTech GmbH, DueNorth BioDev, and Biotheranostics Inc., outside the submitted 
work; and three patents pending. DC reports grant and consultancy fees from 
Roche. All remaining authors have declared no conflicts of interest. 
 
  
REFERENCES 
1. Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-
specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat 
Med 2004; 10: 145-147. 
2. Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab 
in cancer. Lancet Oncol 2010; 11: 1172-1183. 
3. Earl HM, Hiller L, Dunn JA et al. Efficacy of neoadjuvant bevacizumab added 
to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women 
with HER2-negative early breast cancer (ARTemis): an open-label, randomised, 
phase 3 trial. Lancet Oncol 2015; 16: 656-666. 
4. von Minckwitz G, Eidtmann H, Rezai M et al. Neoadjuvant chemotherapy and 
bevacizumab for HER2-negative breast cancer. N Engl J Med 2012; 366: 299-309. 
5. Sikov WM, Berry DA, Perou CM et al. Impact of the addition of carboplatin 
and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-
dense doxorubicin and cyclophosphamide on pathologic complete response rates in 
stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol 
2015; 33: 13-21. 
6. Bear HD, Tang G, Rastogi P et al. Bevacizumab added to neoadjuvant 
chemotherapy for breast cancer. N Engl J Med 2012; 366: 310-320. 
7. Cameron D, Brown J, Dent R et al. Adjuvant bevacizumab-containing therapy 
in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 
3 trial. Lancet Oncol 2013; 14: 933-942. 
8. Miller K, O'Neill AM, Dang CT et al. Bevacizumab (Bv) in the adjuvant 
treatment of HER2-negative breast cancer: Final results from Eastern Cooperative 
Oncology Group E5103. J Clin Oncol 2014; 32: abstract 500. 
9. Symmans WF, Peintinger F, Hatzis C et al. Measurement of residual breast 
cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 
2007; 25: 4414-4422. 
10. (EBCTCG) EBCTCG. Effects of chemotherapy and hormonal therapy for early 
breast cancer on recurrence and 15-year survival: an overview of the randomised 
trials. Lancet 2005; 365: 1687-1717. 
11. von Minckwitz G, Loibl S, Untch M et al. Survival after neoadjuvant 
chemotherapy with or without bevacizumab or everolimus for HER2-negative primary 
breast cancer (GBG 44-GeparQuinto)dagger. Ann Oncol 2014; 25: 2363-2372. 
12. Sikov W, Berry D, Perou C et al. Abstract S2-05: Event-free and overall 
survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin 
and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 
(Alliance). Cancer Research 2016; 76: S2-05-S02-05. 
13. Hatzis C, Symmans WF, Zhang Y et al. Relationship between Complete 
Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative 
Breast Cancer. Clin Cancer Res 2016; 22: 26-33. 
14. Earl H, Provenzano E, Abraham J et al. Neoadjuvant trials in early breast 
cancer: pathological response at surgery and correlation to longer term outcomes - 
what does it all mean? BMC Med 2015; 13: 234. 
15. DeMichele A, Yee D, Berry DA et al. The Neoadjuvant Model Is Still the 
Future for Drug Development in Breast Cancer. Clin Cancer Res 2015; 21: 2911-
2915. 
16. Gianni L, Eiermann W, Semiglazov V et al. Neoadjuvant and adjuvant 
trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): 
follow-up of a randomised controlled superiority trial with a parallel HER2-negative 
cohort. Lancet Oncol 2014; 15: 640-647. 
17. Berruti A, Amoroso V, Gallo F et al. Pathologic complete response as a 
potential surrogate for the clinical outcome in patients with breast cancer after 
neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. J Clin 
Oncol 2014; 32: 3883-3891. 
18. Cortazar P, Zhang L, Untch M et al. Pathological complete response and 
long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 
2014; 384: 164-172. 
19. Allegra CJ, Yothers G, O'Connell MJ et al. Bevacizumab in stage II-III colon 
cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-
08 trial. J Clin Oncol 2013; 31: 359-364. 
20. Corrie PG, Marshall A, Dunn JA et al. Adjuvant bevacizumab in patients with 
melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a 
multicentre, open-label, randomised controlled phase 3 study. Lancet Oncol 2014; 
15: 620-630. 
21. Perren TJ, Swart AM, Pfisterer J et al. A phase 3 trial of bevacizumab in 
ovarian cancer. N Engl J Med 2011; 365: 2484-2496. 
22. Burger RA, Brady MF, Bookman MA et al. Incorporation of bevacizumab in 
the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473-2483. 
23. Boocock CA, Charnock-Jones DS, Sharkey AM et al. Expression of vascular 
endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl 
Cancer Inst 1995; 87: 506-516. 
24. Conley SJ, Gheordunescu E, Kakarala P et al. Antiangiogenic agents 
increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl 
Acad Sci U S A 2012; 109: 2784-2789. 
25. Gourley C, McCavigan A, Perren T et al. Molecular subgroup of high-grade 
serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. 
American Society of Clinical Oncology 2014; 32 abstract 5502. 
 
  
Figures 
Figure 1: Consort diagram 
Figure 2: Survival curves by randomised treatment arm 
a) Disease-Free Survival 
b) Overall Survival 
Figure 3: Treatment Effect by pathological response 
a) Disease-Free Survival from Surgery 
b) Overall Survival from Surgery 
Tables 
Table 1: Patient Characteristics and Response to Treatment 
Table 2: Response Rates from the Central Review of Pathology Specimens, 
across Randomised Treatment Arms 
 
Table 1: Patient Characteristics and Response to Treatment 
 
Full trial population 
 
Central pathology sample with 
primary endpoint assessable 
Central pathology sample 
with RCB assessable 
 (n=800) (n=681) (n=587) 
 n (%) n (%) n (%) 
Patient Characteristics    
Randomised treatment      Bev+D-FEC 399 (50%) 344 (51%) 290 (49%) 
 D-FEC 401 (50%) 337 (49%) 297 (51%) 
Age <50 years old 543 (68%) 458 (67%) 393 (67%) 
 >50 years old 257 (32%) 223 (33%) 194 (33%) 
ER status Negative (Allred score 0-2) 248 (31%) 211 (31%) 194 (33%) 
 Weakly positive (Allred score 3-5) 75 (9%) 68 (10%) 60 (10%) 
 Strongly positive (Allred score 6-8) 477 (60%) 402 (59%) 333 (57%) 
Tumour size <50mm 635 (79%) 541 (79%) 472 (80%) 
 >50mm 165 (21%) 140 (21%) 115 (20%) 
50
51
52
53
54
55
56
57
58
59
60
Clinical involvement of Yes 417 (52%) 354 (52%) 299 (51%) 
axillary nodes No 383 (48%) 327 (48%) 288 (49%) 
Inflammatory or locally Yes 149 (19%) 120 (18%) 103 (18%) 
advanced disease or both No 651 (81%) 561 (82%) 484 (82%) 
     
Response to Treatment     
pCR Yes - 130 (19%) 121 (21%) 
 No - 551 (81%) 466 (79%) 
RCB category 0 - - 121 (21%) 
 1 - - 90 (15%) 
 2 - - 290 (49%) 
 3 - - 86 (15%) 
pCR = Central pathology sample review shows pathological complete response in all breast tumours AND absence of disease in all removed 
axillary lymph nodes; RCB = residual cancer burden
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Figure 1: Consort diagram  
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Table 2: Response Rates from the Central Review of Pathology Specimens, 
across Randomised Treatment Arms 
 Bev+D-FEC D-FEC  
 N (%) N (%) P (adjusted P*) 
pCR (n=681)                                                                                       
Yes 77 (22%) 53 (16%) 003 (003) 
No 267 (78%) 284 (84%)  
RCB class (n=587)     
0 72 (25%) 49 (16%) 0004 (0004) 
1 46 (16%) 44 (15%)  
2 138 (47%) 152 (51%)  
3 34 (12%) 52 (18%)  
* Adjusted for the five stratification variables. 
pCR: pathological complete response in all breast tumours AND absence of disease in all 
removed axillary lymph nodes 
RCB: residual cancer burden 
 
 
  
 
 
Figure 2: Survival curves by randomised treatment arm  
a) Disease-Free Survival  
b) Overall Survival  
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Figure 3: Treatment Effect by pathological response  
a) Disease-Free Survival from Surgery  
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Figure 3: Treatment Effect by pathological response  
b) Overall Survival from Surgery  
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Supplementary Table 1: Patients achieving a pCR, split by DFS event ( =129) 
 Bev+D-FEC (n=77) D-FEC (n=52) 
 DFS event  
(n=16 (21%)) 
No DFS event  
(n=61 (79%)) 
DFS event  
(n=3 (6%)) 
No DFS event  
(n=49 (94%)) 
ER status      
Neg 9 (56%) 38 (62%) 2 (67%) 30 (61%) 
Weak pos 4 (25%) 13 (21%) 1 (33%) 7 (14%) 
Pos 3 (19%) 10 (17%) - 12 (25%) 
     
Surgery type *     
Mastectomy 6 (38%) 18 (30%) 1 (33%) 13 (27%) 
Breast Conserving 10 (63%) 43 (70%) 2 (67%) 37 (76%) 
Re-excision - 1 (2%) - 2 (4%) 
Reconstruction 2 (13%) 2 (3%) - 2 (4%) 
Axillary Sampling 1 (6%) 7 (11%) 1 (33%) 4 (8%) 
Axillary Clearance 8 (50%) 26 (43%) 2 (67%) 22 (45%) 
     
Radiotherapy given?     
Reported 14 (88%) 52 (85%) 2 (67%) 39 (80%) 
Not reported 2 (12%) 9 (15%) 1 (33%) 10 (20%) 
     
Local     
Yes 6 (38%) - - - 
No 10 (62%) 61 (100%) 3 (100%) 49 (100%) 
     
Distant     
Yes 12 (75%) - 3 (100%) - 
No 4 (25%) 61 (100%) - 49 (100%) 
     
Dead     
Yes 12 (75%) - 3 (100%) - 
No 4 (25%) 61 (100%) - 49 (100%) 
     
Cause of death *     
Metastatic Breast Cancer 12 (100%) - 3 (100%) - 
Acute renal failure 1 (8%) - - - 
Ovarian second primary 1 (8%) - - - 
* Patients can have multiple surgery types and multiple causes of death 
 
